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Introduction
Serum sickness is an allergic disease that follows the
administration of a foreign antigenic material, most
commonly caused by injecting a protein or haptenic
drug.1 The disease is a type III hypersensitivity reac-
tion mediated by deposits of circulating immune
complexes in small vessels, which leads to comple-
ment activation and subsequent inflammation.
Antivenin is 1 of the most frequent proteins known to
elicit serum sickness.
Poisonous snakebites are an epidemiological prob-
lem worldwide, including in Taiwan.2 The mainstay of
treatment for venomous snakebites is antivenin,3 rely-
ing on an antidote to neutralize the venom to achieve
detoxification. In the literature, the incidence of
serum sickness induced by antivenin (Crotalidae)
polyvalent (ACP) in the USA is reported to be as high
as 40–80% in snakebite patients.3,4 In Taiwan, however,
no cases of serum sickness related to antivenin have
been reported, even with approximately 300–500
snakebite victims per year.2 We report a Taiwanese
patient who presented with serum sickness after receiv-
ing antivenin therapy for snakebite.
Case Report
A 59-year-old male was bitten by a Trimeresurus stej-
negeri snake on the dorsum of the left hand while work-
ing in a field. One hour later, he presented to the China
Medical University Hospital in Taichung, Taiwan. The
dead snake was also available for species verification. On
presentation, our patient’s vital signs were stable,
although he complained of pain in the bitten hand.
Two fang marks were found with surrounding swelling
and ecchymosis on the dorsum of the left hand.
Laboratory data were unremarkable. In total, 20 vials of
polyvalent antivenin (for T. stejnegeri and Protobothrops
mucrosquamatus) were prescribed in the first 3 days
due to progressive local swelling and persistent local
painful sensation. Furthermore, fever was noted on the
2nd day after admission, and antibiotics (amoxicillin
clavulanate) were prescribed for a total of 5 days for the
treatment of cellulitis. No bacteria were identified in
blood culture. The patient was discharged 7 days after
admission with an improved condition.
However, intermittent fever and headaches devel-
oped 3–4 days after discharge. Pain, swelling, local heat,
and limited joint movement in multiple joints of all 
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4 limbs developed 2 days later. A diffuse skin rash
with multiple erythematous itching papules and
petechiae over both lower legs were also noted.
Under the suspicion of serum sickness resulting from
the antivenin treatment, the patient was readmitted
for steroid treatment. Laboratory data showed an
erythrocyte sedimentation rate of 30 mm/hand and a
C-reactive protein level of 2.37 mg/dL (normal value, 
0.8 mg/dL). C3 was 129 mg/dL (normal range,
79–152 mg/dL), C4 was 20.2 mg/dL (normal range,
16–38 mg/dL), and antinuclear antibodies and
rheumatoid factor were negative. The episodes of arthri-
tis and skin lesions improved after steroid treatment. The
patient was discharged 5 days later.
Discussion
Serum sickness is the prototypic example of type III or
immune-complex mediated hypersensitivity disease.1
The reaction requires the presence of the antigen
coincident with antibodies directed against the anti-
gen, leading to the formation of an antigen-antibody
or immune complex. These complexes are normally
cleared by the mononuclear phagocyte system. Excess
immune complexes may form in the circulation and
deposit in tissues or form directly in the involved tis-
sues if this system is not functioning well or is saturated
by the immune complex load. The presence of immune
complexes in parenchymal tissues, such as joints or
lymph nodes, triggers an inflammatory response.
Our patient presented with the typical signs and
symptoms of serum sickness such as rash, fever, malaise,
and polyarthralgias or polyarthritis, which occur 1–2
weeks after the first exposure to the responsible agent.
The laboratory results were also suggestive of inflam-
mation. The patient’s symptoms resolved within a few
weeks of discontinuing the agent. Administration of
antivenin treatment is the most plausible reason to
explain the occurrence of serum sickness in this patient.
Products derived from horse serum and adminis-
tered as antitoxins or antivenin are historically the most
common cause of serum sickness. Previously, there was
only 1 antivenin available in the USA (ACP) for the
treatment of pit viper envenomation. The incidence of
serum sickness induced by ACP can be as high as
40–80%.4,5 In a study by LoVecchio et al,4 patients of
snakebite received an average of 38 vials of ACP (range,
5–62). The incidence of serum sickness can be expected
to be greater than 50% in cases receiving 30–39 vials of
antivenin and might reach 100% at doses of 40 or more
vials. In recent years, a new antivenin (CroFab) com-
posed of purified Fab segments specific to indigenous
snake species has been developed, and this has been
shown to have a higher efficacy and fewer immuno-
logical effects.6 CroFab has a mean serum sickness
incidence of less than 10%, with a range of 3–16%.7
The possible reasons for Fab antivenin-induced serum
sickness are attributed to a high concentration of Fab
fragments and contaminated Fc components.8
In Taiwan, however, reports of antivenin-induced
serum sickness are rare, even with 300–500 snakebite
victims per year.2 This low frequency may be due to
the efficacy and dosage of antivenins administered to
treat snakebites in Taiwan. There are only 6 epidemi-
ologically important poisonous snakes2 and 4 kinds of
lyophilized antivenin available to cover these 6
snakebites. These antivenins are produced by the
Centers for Disease Control, Taiwan, in the form of
F(ab)2 fragments of an equine antigen. The anti-
venins contain 2,000 units per vial. A dose of 1–3
vials of antivenin should be adequate to treat mild-to-
moderate snakebites, with the possible exception of a
cobra snakebite.2 These antivenins also have a low risk
to induce acute adverse reactions.9 The patient in this
report received a total of 20 vials of antivenin due to
poor clinical response and eventually presented with
symptoms consistent with serum sickness.
Serum sickness also results from the injection of
other heterogeneous foreign proteins or haptens, and
certain medications may cause serum sickness-like reac-
tions. Cephalosporin antibiotics are 1 of the prototypes,
with high rates of sickness-like reactions reported in
children.10 A serum sickness-like reaction also occurs
after penicillin administration and may be seen in some
patients who receive prolonged, high-dose intravenous
penicillin.11,12 During his first hospitalization after the
snakebite, the patient in this case had been treated with
amoxicillin clavulanate for possible cellulitis of the left
hand. However, based on the time course, the episode
of serum sickness developed 3–4 days after discharge
and was most likely due to the antivenin. However, the
role of antibiotics in the occurrence of serum sickness
requires further investigation.
In conclusion, reports of serum sickness due to
antivenins against snake venom are rare in Taiwan.
However, physicians should remain alert to the
potential for serum sickness in cases where large doses
of antivenin are administered for snakebite.
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